Introduction
============

Approximately 71 million individuals worldwide are affected by hepatitis C virus (HCV) infection, and the estimated global prevalence rate is 1.0% ([@B1]). Injection drug use and unsafe healthcare practices are well-known risk factors for HCV infection. Chronic hepatitis occurs in 54-86% cases with acute HCV infection ([@B2]), and it can lead to cirrhosis and hepatocellular carcinoma.

Acute liver failure (ALF), defined as evidence of coagulopathy, usually with a prothrombin time-international normalized ratio (PT-INR) ≥1.5, and any degree of an altered sensorium within 8 weeks of the first symptoms in the absence of prior liver disease ([@B3]), is considered a rare complication of acute HCV infection ([@B4]-[@B6]), although reports are controversial. To our knowledge, only a few cases of ALF due to HCV have been reported to date ([@B7],[@B8]).

Direct-acting antiviral (DAA) therapy has been proven to be safe and effective for managing chronic HCV infection ([@B9],[@B10]); however, its role in the management of acute infection remains unclear. Furthermore, little is known about the safety and efficacy of DAA for severe acute HCV infection associated with a high risk of ALF.

We herein report a rare case involving an elderly Japanese man with acute HCV monoinfection associated with a high risk of ALF who was successfully treated with ledipasvir (LDV) and sofosbuvir (SOF) therapy.

Case Report
===========

A 72-year-old Japanese man with yellow discoloration of the sclera and epigastrium for 7 and 4 days, respectively, and liver dysfunction was referred to Takasaki General Medical Center for an evaluation. He was not taking any medication other than famotidine and teprenone that had been prescribed by a local clinic two days before admission. He had no history of underlying liver diseases, alcohol abuse, blood transfusion, illicit or illegal intravenous drug use, or sexual contact with a hepatitis carrier in the previous six months. He had received 18 hyaluronic acid injections for right knee osteoarthritis over the last 6 months at another local clinic.

Our physical examination revealed mild conjunctival jaundice and tenderness over the epigastrium. No degree of an altered sensorium, including flapping tremor, was observed. Laboratory data on admission were as follows: PT-INR, 1.54; total bilirubin, 4.6 mg/dL; aspartate aminotransferase, 3,111 IU/L; and alanine aminotransferase (ALT), 3,857 IU/L. A third-generation enzyme-linked immunosorbent assay (ARCHITECT, Abbott Japan, Chiba, Japan) revealed anti-HCV positivity, although a test performed 4 years earlier had shown negativity. The anti-HCV titer was 4.27 (cut-off: 1.00), which increased to 10.1 at 2 weeks after admission. HCV-RNA was detected by reverse transcription polymerase chain reaction (COBAS TaqMan HCV assay, Version 2.0; Roche Molecular Diagnostics, Tokyo, Japan). The HCV genotype was 1b, and the interleukin-28B (IL28B) genotype (rs8099917) was T/T. Serological screening for the other hepatitis viruses, including IgM-hepatitis A virus (HAV), IgG-HAV, hepatitis B virus (HBV) markers (hepatitis B antigen, hepatitis B surface antibody, hepatitis B core antibody, HBV-DNA), and IgA-hepatitis E virus, showed negative findings, while that for Epstein-Barr virus and cytomegalovirus showed an infection history. A human immunodeficiency virus (HIV) antibody test showed negative findings ([Table 1](#t001){ref-type="table"}).

###### 

Laboratory Data.

  Variable           Results                  Variable                                  Results              
  --------------- -- --------- -------------- ---------- ------------------------------ --------- ---------- ---------------
  WBC                64        ×10^2^/mm^3^              CRP                                      0.56       mg/dL
  Neutrophil         55.0      \%                        NH3                                      64         μg/dL
  Eosinophil         3.0       \%                        TSH                                      3.51       µIU/mL
  Basophil           1.0       \%                        Free T3                                  2.39       pg/mL
  Monocytes          8.0       \%                        Free T4                                  1.17       ng/dL
  Lymphocytes        33.0      \%                        IgG                                      1,066      mg/dL
  RBC                495       ×10^4^/mm^3^              IgA                                      297        mg/dL
  Hemoglobin         15.3      g/dL                      IgM                                      171        mg/dL
  Platelet           16.5      ×10^4^/mm^3^              ANA                                      \<40       Times
  PT                 42        \%                        AMA-M2                                   \<20       Times
  PT-INR             1.54                                IgM-HAV antibody                         Negative   
  APTT               41.5      sec                       IgG-HAV antibody                         Negative   
  Total protein      6.7       g/dL                      Hepatitis B surface antigen              Negative   
  Albumin            4.2       g/dL                      Hepatitis B surface antibody             Negative   
  T. bil.            4.6       mg/dL                     Hepatitis B core antibody                Negative   
  AST                3,111     IU/L                      HBV-DNA                                  Negative   
  ALT                3,857     IU/L                      Hepatitis C antibody                     4.26       COI
  LDH                1,883     IU/L                      HCV-RNA                                  6.9        log~10~ IU/mL
  ALP                642       IU/L                      Genotype of HCV                          1b         
  γ-GTP              263       IU/L                      NS5A RASs                                None       
  ChE                308       IU/L                      IL28B (rs8099917)                        T/T        
  BUN                20        mg/dL                     IgA-HEV antibody                         Negative   
  Creatinine         1.15      mg/dL                     IgM-EBV VCA                              Negative   
  eGFR               51.2      mL/min                    IgG-EBV VCA                              Positive   
  Blood glucose      163       mg/dL                     IgG-EBV EBNA                             Positive   
  Sodium             137       mEq/L                     IgM-CMV                                  Negative   
  Potassium          4.4       mEq/L                     IgG-CMV                                  Positive   
  Chloride           107       mEq/L                                                                         

ALT: alanine aminotransferase, ALP: alkaline phosphatase, AMA: anti-mitochondrial antibody, ANA: anti-nuclear antibody, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, BUN: blood urea nitrogen, CMV: cytomegalovirus, CRP: C-reactive protein, EBV: Epstein-Barr virus, EBNA: Epstein-Barr virus nuclear antigen, eGFR: estimated glomerular filtration rate, HAV: hepatitis A virus, HBV: hepatitis B virus, HCV: hepatitis C virus, HEV: hepatitis E virus, IL28B: interleukin-28B genotype, LDH: lactate dehydrogenase, PT: prothrombin time, PT-INR: prothrombin time-international normalized ratio, RASs: resistance-associated substitutions, RBC: red blood cell, γ-GTP: gamma-glutamyltransferase, T. bil.: total bilirubin, TSH: thyroid stimulating hormone, VCA: virus capsid antigen, WBC: white blood cell

Because of coagulopathy, we performed a transjugular liver biopsy (TJLB) instead of a percutaneous liver biopsy under ultrasound guidance three days after admission ([@B11]). The liver specimen showed extensive neutrophilic and lymphocytic infiltration with regeneration, which indicated submassive hepatic necrosis ([Fig. 1](#g001){ref-type="fig"}). Five days after admission, an altered sensorium, including flapping tremor, was still not observed, and his PT-INR and total bilirubin level showed increases of 1.70 and 17.8 mg/dL, respectively. The Model for End-Stage Liver Disease (MELD) ([@B12]) score was determined to be 25, and the risk of ALF was estimated to be 48% according to the Japan Hepatic Encephalopathy Prediction Model (JHEPM) ([@B13]).

![Microscopic findings for a liver specimen obtained from a 72-year-old Japanese man with acute severe hepatitis C virus monoinfection associated with a high risk of acute liver failure. (a) A histopathological analysis shows extensive neutrophilic and lymphocytic infiltration with regeneration, which indicates submassive hepatic necrosis. (b) A councilman body is also seen (white arrow).](1349-7235-58-2969-g001){#g001}

Following institutional review board approval (approval number: H30-81) and the acquisition of informed consent from the patient, we initiated oral treatment with the NS5A inhibitor LDV (90 mg) and NS5B inhibitor SOF (400 mg; Harvoni, Gilead Sciences, Tokyo, Japan) for 12 weeks. We also administered intravenous methylprednisolone 1 g for 3 days. His PT-INR promptly improved to 1.41 after 4 days of combination therapy LDV/SOF with methylprednisolone. Because the total serum bilirubin level increased to 30.3 mg/dL, plasma bilirubin absorption was performed three times. Consequently, the total bilirubin level gradually decreased. HCV-RNA levels were 6.2, 4.4, 3.4, 2.1, and \<1.2 log~10~IU/mL at baseline and 1, 2, 4, and 6 weeks after the start of LDV/SOF therapy, respectively, and they were undetectable at 8 weeks. There were no adverse events associated with LDV/SOF therapy, and the patient was discharged at 73 days after admission.

A sustained virological response (SVR) was achieved at 12 (SVR 12) and 24 (SVR 24) weeks after treatment. The clinical course and HCV-RNA levels are shown in [Fig. 2](#g002){ref-type="fig"}. The full genomic sequence of an HCV isolate (KT4-Gt1b) recovered from the patient was determined according to previously described methods ([@B14],[@B15]) and deposited in the DDBJ/EMBL/GenBank databases under the accession number LC462122. There were no nonstructural protein (NS) 5A resistance-associated substitutions (RASs).

![Clinical course and changes in hepatitis C virus (HCV) RNA levels in a 72-year-old man with acute severe hepatitis C virus monoinfection associated with a high risk of acute liver failure. (a) The prothrombin time-international normalized ratio (PT-INR) and total bilirubin level showed increase of 1.70 and 17.8 mg/dL, respectively, 5 days after admission. This indicated a high risk of acute liver failure. Combination therapy with ledipasvir (LDV) 90 mg and sofosbuvir (SOF) 400 mg was administered for 12 weeks, with intravenous injection of methylprednisolone (mPSL) 1 g for 3 days. This improved the PT-INR, but the total bilirubin level increased to 30.3 mg/dL. Plasma bilirubin absorption was performed three times, with a gradual decrease in the total bilirubin level. (b) The HCV-RNA levels were 6.2, 4.4, 3.4, 2.1, and \<1.2 log~10~IU/mL at baseline and 1, 2, 4, and 6 weeks, respectively, and they were undetectable at 8 weeks after initial LDV/SOF treatment. ALT: alanine aminotransferase, LLOQ: lower limit of quantification](1349-7235-58-2969-g002){#g002}

Discussion
==========

To our knowledge, this was the first case of severe acute hepatitis C monoinfection treated with DAA therapy for the prevention of ALF. We diagnosed acute HCV infection based on HCV-RNA positivity, anti-HCV seroconversion, and an ALT level of \>20 times the upper limit of normal ([@B16]). Our diagnosis was also supported by the increased anti-HCV antibody level at 2 weeks after admission and the negative screening test findings for other liver diseases. Repeated hyaluronic acid injections for osteoarthritis treatment were suspected to be the cause of HCV transmission. The MELD score is recommended as a prognostic scoring system for patients with acute liver disease ([@B17]). In the present case, the MELD score was determined to be 25, and the risk of ALF was estimated to be 48% according to JHEPM ([@B13]). Accordingly, we prescribed oral LDV/SOF therapy for 12 weeks and intravenously injected methylprednisolone 1 g for 3 days, believing that rapid HCV clearance and temporary suppression of the immune response would prevent ALF development. There were no treatment-related adverse events, and the patient was discharged 73 days after admission.

A previous study documented spontaneous remission in approximately 25% of patients with acute HCV monoinfection ([@B18]). Potential favorable factors for spontaneous HCV clearance include female sex ([@B19],[@B20]), symptomatic disease ([@B19],[@B21]), the absence of HIV coinfection ([@B22],[@B23]), the IL28B CC genotype ([@B20],[@B21],[@B24]), and the HCV genotype 1 ([@B20],[@B25]). However, these factors have not been fully verified. During the period of interferon-based regimens, the rate of SVR was higher and its duration shorter in cases of acute hepatitis C than in those of chronic hepatitis C.

At present, DAA is the established treatment for patients with chronic HCV infection because of its superior efficacy and safety ([@B9],[@B10]). However, the efficacy and safety of DAA therapy for acute HCV infection remain unclear. Successful eradication of HCV infection has several health benefits, including alleviation of liver inflammation, regression of liver fibrosis, and a reduction in the risk of hepatocellular carcinoma ([@B9],[@B10]). However, according to the latest European Association for the Study of the Liver guidelines ([@B10]), acute HCV infection should be treated with DAA therapy in order to prevent a transition to chronicity. Previous studies ([@B26]-[@B28]) have shown that the SVR 12 rate after SOF and ribavirin (RBV) therapy for acute or recent HCV monoinfection or HCV/HIV coinfection was 32-92%. Other studies ([@B29]-[@B32]) evaluating acute HCV infection treated with LDV/SOF for 4-12 weeks have reported an SVR 12 rate of 77-100% ([Table 2](#t002){ref-type="table"}). Of note, serious drug-related adverse events were not observed in these previous studies ([@B26]-[@B32]). In those studies, HCV-RNA was undetectable at 4 weeks in 70-100% patients ([@B29]-[@B32]), while it was undetectable at 2 weeks in approximately 80% patients and at 4 weeks in all patients in phase III clinical trials evaluating chronic HCV infection treated with LDV/SOF ([@B33],[@B34]). The optimal DAA regimen and duration of DAA therapy for acute HCV infection failed to be clarified by these studies.

###### 

Acute Hepatitis C Mono-infection and HIV Co-infection Treated with DAA Therapies.

  References   Infection                                          Number of patients   Median age        Male             Genotype                                                 Median baseline HCV-RNA (log~10~IU/mL)   DAA regimen     Duration of DAA therapies   Symptomatic   IL28B CC   Undectable          Drug-related serious AE               
  ------------ -------------------------------------------------- -------------------- ----------------- ---------------- -------------------------------------------------------- ---------------------------------------- --------------- --------------------------- ------------- ---------- ------------------- ------------------------- ----------- --------
  \(26\)       Recent HCV (\<12 months) HIV co-infection (n=14)   19                   41                17 (89%)         1a (68%), 2a (5%), 3a (21%), 3 unable to subtype 1(5%)   5.4                                      SOF+RBV         6 weeks                     4 (21%)       12 (60%)   15 (79%)            17 (89%)                  6 (32%)     0 (0%)
  \(27\)       HIV co-infection                                   17                   45                100 (100%)       1a (65%), 1b (12%), 1 subtype unknown (12%), 2 (6%)      6.4                                      SOF+RBV         12 weeks                    NA            4 (24%)    12 (71%)            17 (100%)                 10 (59%)    0 (0%)
  \(28\)       HIV co-infection                                   12                   43                100 (100%)       1a (83%), 1b (17%)                                       4.5                                      SOF+RBV         12 weeks                    0 (0%)        7 (63%)    NA                  11 (92%)                  11 (92%)    0 (0%)
  \(29\)       HCV mono-infection                                 \(A\) 14             \(A\) 27 (mean)   \(A\) 12 (86%)   \(A\) 1a (50%), 1b (50%)                                 \(A\) 3.08 (mean)                        \(A\) LDV/SOF   \(A\) 4 weeks               NA            NA         \(A\) 14 (100%)     14 (100%)                 14 (100%)   NA
                                                                  \(B\) 15             \(B\) 31 (mean)   \(B\) 14 (93%)   \(B\) 1a (47%), 1b (53%)                                 \(B\) 3.2 (mean)                         \(B\) SIM/SOF   \(B\) 8 weeks                                        \(B\) 14 (93%)      14 (93%)                  13 (87%)    
  \(30\)       HCV mono-infection                                 20                   49                12 (60%)         1a (55%), 1b (45%)                                       4.04                                     LDV/SOF         8 weeks                     19 (95%)      12 (60%)   14 (70%)            20 (100%)                 20 (100%)   0 (0%)
  \(31\)       HIV co-infection                                   26                   43                100 (100%)       1a (73%), 4 (27%)                                        5.6                                      LDV/SOF         6 weeks                     2 (8%)        12 (46%)   23 (89%) (\<LLOQ)   15 (96%) (\<LLOQ)         20 (77%)    0 (0%)
  \(32\)       HIV co-infection                                   25                   38                100 (100%)       1a (92%), 1b (8%)                                        5.1                                      LDV/SOF         12 weeks                    2 (8%)        13 (52%)   NA                  NA                        25 (100%)   0 (0%)

AE: adverse event, DAA: direct-acting antivirals, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IL28B: interleukin-28B genotype, LDV: ledipasvir, LLOQ: lower limit of quantification, NA: not available, RBV: ribavirin, SIM: simeprevir, SOF: sofosbuvir, SVR: sustained virological response

We prescribed LDV/SOF therapy to our patient in order to alleviate the liver inflammation and prevent ALF, not to achieve SVR 12 and prevent progression to chronicity. We chose the LDV/SOF regimen because LDV/SOF, and not SOF/RBV, is available for HCV genotype 1 treatment in Japan. In addition, protease inhibitor regimens, including glecaprevir/pibrentasvir and grazoprevir/elbasvir, are contraindicated for patients with decompensated cirrhosis (Child-Pugh class B or class C) ([@B10]). We therefore considered LDV/SOF to be a safer regimen for acute hepatitis C patients with severe jaundice than protease regimens. We selected a duration of 12 weeks because HCV-RNA was detectable at 6 weeks and completely undetectable at 8 weeks after therapy initiation. The IL28B genotype in our case was T/T (rs8099917), and there were no NS5A RASs. Accordingly, we expected that HCV would be rapidly cleared by the patient\'s immune system and antiviral agents. The reason for this prolonged viremia remains uncertain. In addition, we had to carefully consider whether or not the prescription of DAA would be beneficial, as patients with severe acute infection and a high risk of ALF, such as the present patient, were not included in the previous reference studies.

In the present case, we performed a TJLB in order to obtain not only an accurate liver diagnosis but also to determine the degree of liver necrosis, resulting in a diagnosis of submassive hepatic necrosis. The presumptive diagnosis was changed in about 18% of ALF patients after a liver biopsy, according to previous reports ([@B35],[@B36]). In addition, the degree of liver necrosis determined by a histological liver specimen may help predict the prognosis in ALF patients ([@B35],[@B36]). A routine liver biopsy is not recommended because the risk of such a procedure is higher in patients with coagulopathy than in those without it ([@B17]). Accordingly, caution must be practiced until whether or not the benefit of a liver biopsy outweighs its risk in ALF patients is determined.

Although the efficacy of steroid therapy to ALF patients remains unknown ([@B37]-[@B40]), a previous study suggested that steroid therapy might be effective in patients with acute liver injury before the development of ALF ([@B41]). This study showed that a 40% JHEPM probability, PT-INR of 1.53, and PT of 52% constituted appropriate timing of steroid therapy in order to prevent the development of ALF ([@B41]). It also showed that the PT after four days of steroid therapy was a useful marker for predicting the development of ALF ([@B41]). In the present patient, we administered intravenous methylprednisolone 1 g for 3 days when his JHEPM probability and PT-INR were 48% and 1.70, respectively, suggesting that we used steroid therapy at the appropriate timing; and indeed, his PT-INR was improved after 4 days of steroid therapy. The temporary suppression of the immune response by steroid therapy may also play an important role in preventing the development of ALF. A further study of the efficacy and the appropriate timing of steroid therapy should be conducted.

In conclusion, the findings from the present case suggest that LDV/SOF therapy may be a promising modality for severe acute HCV monoinfection associated with a high risk of ALF.
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